Literature DB >> 19650159

Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis.

Koji Fujita1, Yuichi Nozaki, Koichiro Wada, Masato Yoneda, Yoko Fujimoto, Mihoyo Fujitake, Hiroki Endo, Hirokazu Takahashi, Masahiko Inamori, Noritoshi Kobayashi, Hiroyuki Kirikoshi, Kensuke Kubota, Satoru Saito, Atsushi Nakajima.   

Abstract

UNLABELLED: The specific mechanisms of nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH) pathogenesis remain unknown. In the present study we investigated the differences between NAFL and NASH in terms of liver lipid metabolites and serum lipoprotein. In all, 104 Japanese subjects (50 men and 54 postmenopausal women) with histologically verified NAFL disease (NAFLD) (51 with NAFL, 53 with NASH) were evaluated; all diagnoses were based on liver biopsy findings and the proposed diagnostic criteria. To investigate the differences between NAFL and NASH in humans, we carefully examined (1) lipid inflow in the liver, (2) lipid outflow from the liver, (3) very-low-density lipoprotein (VLDL) synthesis in the liver, (4) triglyceride (TG) metabolites in the liver, and (5) lipid changes and oxidative DNA damage. Most of the hepatic lipid metabolite profiles were similar in the NAFL and NASH groups. However, VLDL synthesis and lipid outflow from the liver were impaired, and surplus TGs might have been produced as a result of lipid oxidation and oxidative DNA damage in the NASH group.
CONCLUSION: A growing body of literature suggests that a deterioration in fatty acid oxidation and VLDL secretion from the liver, caused by the impediment of VLDL synthesis, might induce serious lipid oxidation and DNA oxidative damage, impacting the degree of liver injury and thereby contributing to the progression of NASH. Therefore, dysfunctional VLDL synthesis and release may be a key factor in progression to NASH.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19650159     DOI: 10.1002/hep.23094

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  96 in total

1.  Induction of microsomal triglyceride transfer protein expression is a candidate mechanism by which ezetimibe therapy might exert beneficial effects in patients with nonalcoholic steatohepatitis.

Authors:  Masato Yoneda; Koji Fujita; Kento Imajo; Hironori Mawatari; Hiroyuki Kirikoshi; Satoru Saito; Atsushi Nakajima
Journal:  J Gastroenterol       Date:  2010-12-22       Impact factor: 7.527

2.  Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease.

Authors:  Kris V Kowdley; Patricia Belt; Laura A Wilson; Matthew M Yeh; Brent A Neuschwander-Tetri; Naga Chalasani; Arun J Sanyal; James E Nelson
Journal:  Hepatology       Date:  2011-12-06       Impact factor: 17.425

3.  Methionine adenosyltransferase 1A gene deletion disrupts hepatic very low-density lipoprotein assembly in mice.

Authors:  Ainara Cano; Xabier Buqué; Maite Martínez-Uña; Igor Aurrekoetxea; Ariane Menor; Juan L García-Rodríguez; Shelly C Lu; M Luz Martínez-Chantar; José M Mato; Begoña Ochoa; Patricia Aspichueta
Journal:  Hepatology       Date:  2011-12       Impact factor: 17.425

Review 4.  Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine.

Authors:  Mazen Noureddin; José M Mato; Shelly C Lu
Journal:  Exp Biol Med (Maywood)       Date:  2015-04-13

5.  Saturated fat and cholesterol are critical to inducing murine metabolic syndrome with robust nonalcoholic steatohepatitis.

Authors:  Jamie E Mells; Ping P Fu; Pradeep Kumar; Tekla Smith; Saul J Karpen; Frank A Anania
Journal:  J Nutr Biochem       Date:  2014-12-06       Impact factor: 6.048

6.  Hepatocyte-specific depletion of ubiquitin regulatory X domain containing protein 8 accelerates fibrosis in a mouse non-alcoholic steatohepatitis model.

Authors:  Norihiro Imai; Michitaka Suzuki; Yoji Ishizu; Teiji Kuzuya; Takashi Honda; Kazuhiko Hayashi; Masatoshi Ishigami; Yoshiki Hirooka; Tetsuya Ishikawa; Hidemi Goto; Toyoshi Fujimoto
Journal:  Histochem Cell Biol       Date:  2017-04-18       Impact factor: 4.304

7.  Nonalcoholic fatty liver disease: from lipid profile to treatment.

Authors:  Kouichi Miura; Hirohide Ohnishi
Journal:  Clin J Gastroenterol       Date:  2012-06-17

8.  Hepatocellular ballooning in NASH.

Authors:  Stephen Caldwell; Yoshihiro Ikura; Daniela Dias; Kosuke Isomoto; Akito Yabu; Christopher Moskaluk; Patcharin Pramoonjago; Winsor Simmons; Harriet Scruggs; Nicholas Rosenbaum; Timothy Wilkinson; Patsy Toms; Curtis K Argo; Abdullah M S Al-Osaimi; Jan A Redick
Journal:  J Hepatol       Date:  2010-06-25       Impact factor: 25.083

9.  Oral choline tolerance test as a novel noninvasive method for predicting nonalcoholic steatohepatitis.

Authors:  Kento Imajo; Masato Yoneda; Koji Fujita; Takaomi Kessoku; Wataru Tomeno; Yuji Ogawa; Yoshiyasu Shinohara; Yusuke Sekino; Hironori Mawatari; Yuichi Nozaki; Hiroyuki Kirikoshi; Masataka Taguri; Gen Toshima; Junichiro Takahashi; Satoru Saito; Koichiro Wada; Atsushi Nakajima
Journal:  J Gastroenterol       Date:  2013-03-16       Impact factor: 7.527

Review 10.  Autophagy in health and disease. 2. Regulation of lipid metabolism and storage by autophagy: pathophysiological implications.

Authors:  Mark J Czaja
Journal:  Am J Physiol Cell Physiol       Date:  2010-01-20       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.